CD BioGlyco provides an integrated solution to develop carbohydrate-based vaccines according to each customer's scientific needs. We have various advanced technology platforms and high-quality services to meet your requirements. We are confident to be your essential research assistant in the field of glycobiology.
We focuses on carbohydrate-based vaccine development for several years. Our services are divided into polysaccharide vaccine development, tumor-related carbohydrate vaccine development, and glycoconjugate vaccine development by type. According to the sources of carbohydrates, our services include vaccine development of natural carbohydrates, semi-synthetic carbohydrates, and fully synthetic carbohydrates. According to the applications, we provide antibacterial, antifungal, antiparasitic, antiviral, anticancer, and antihelminthic vaccine development. By valent category, we provide monovalent and polyvalent carbohydrate-based vaccine development.
In addition, CD BioGlyco provides customers with carrier protein design services and carbohydrate conjugation services for vaccine development.
Fig.1 Carbohydrate-based vaccines against a variety of diseases. (Morelli, 2011)
We have developed an advanced platform for the design and synthesis of polysaccharide vaccines and polysaccharide conjugate vaccines, and ensure vaccine efficacy and safety through multiple quality control methods.
We focus on the development of tumor vaccines based on tumor-associated carbohydrate antigens (TACAs), providing new perspectives for diseases that lack effective preventive or therapeutic vaccines.
We develop natural carbohydrate-based vaccines by isolating carbohydrate antigens from microbial cultures. And we offer complex purification procedures and analytical tests to ensure vaccine efficacy.
We have made great progress in carbohydrate synthetic chemistry, which allows us to help customers synthesize limited quantities of antigens for the development of semi-synthetic carbohydrate-based vaccines.
We are working on the development of carbohydrate-based antibacterial vaccines against various bacterial strains such as Streptococcus pneumoniae, Haemophilus influenzae and Neisseria meningitidis.
We are dedicated to helping customers develop carbohydrate-based antifungal vaccines for the prevention of fungal infections by using various polysaccharides on the fungal cell wall as targets.
We have developed a dedicated research platform to help clients explore preventive carbohydrate vaccine strategies against a variety of parasitic diseases such as malaria, toxoplasmosis and leishmaniasis.
We have established several effective strategies to help our clients design and develop carbohydrate-based antiviral vaccines, with a focus on HIV and COVID-19 vaccines.
We focus on the synthesis of tumor-associated glycan antigens (TACAs) on the tumor surface to help our clients develop potential carbohydrate-based anti-cancer vaccines.
We have established several efficient strategies to help clients develop monovalent carbohydrate vaccines for immunization against a single antigen or a single microorganism.
We provide customers with a wide range of high-quality carrier proteins synthesis services as well as specialized design services for new carrier proteins for the development of glycoconjugate vaccines.
CD BioGlyco has extensive experience in carbohydrate-based vaccine development. We offer a wide range of carbohydrate conjugation services for vaccine development according to our clients' scientific needs.
CD BioGlyco is committed to providing high-quality carbohydrate-based vaccine design and synthesis services to promote our clients' vaccine development projects. Our experienced scientific research personnel will customize a rational program according to your needs, and finally, obtain carbohydrate antigens with a certain structure and high immunogenicity. If you are interested in our services, please contact us for more detailed information.